Abstract
Tumour necrosis factor antagonists (anti-TNFα) have become an invaluable treatment against chronic inflammatory diseases. Individuals treated with anti-TNFα have more than a fourfold increased risk of tuberculosis (TB) reactivation depending on the clinical setting and the TNF-antagonist used. All candidates for anti-TNFα treatment in Denmark should be evaluated for possible latent TB using history of exposure, chest X-ray and an interferon-γ release assay. Preventive chemotherapy is recommended for all individuals with latent TB infection before initiation of anti-TNFα as it is expected to reduce the risk of progression to active TB.
| Bidragets oversatte titel | Screening for tuberculosis infection prior to medical therapy |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 173 |
| Udgave nummer | 12 |
| Sider (fra-til) | 893-6 |
| Antal sider | 4 |
| ISSN | 0041-5782 |
| Status | Udgivet - 2011 |
Emneord
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Humans
- Immunologic Tests
- Immunosuppressive Agents
- Interferon-gamma
- Latent Tuberculosis
- Risk Factors
- Tuberculin Test
- Tuberculosis, Pulmonary
- Tumor Necrosis Factor-alpha
Fingeraftryk
Dyk ned i forskningsemnerne om 'Screening for tuberkuloseinfektion før behandling med biologiske lægemidler'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS